` PEN (Penumbra Inc) vs S&P 500 Comparison - Alpha Spread

PEN
vs
S&P 500

Over the past 12 months, PEN has significantly outperformed S&P 500, delivering a return of 36% compared to the S&P 500's 6% growth.

Stocks Performance
PEN vs S&P 500

Loading
PEN
S&P 500
Add Stock

Performance Gap
PEN vs S&P 500

Loading
PEN
S&P 500
Difference

Performance By Year
PEN vs S&P 500

Loading
PEN
S&P 500
Add Stock

Competitors Performance
Penumbra Inc vs Peers

Penumbra Inc
Glance View

Economic Moat
Narrow
Market Cap
10.7B USD
Industry
Health Care

In the bustling landscape of medical technology, Penumbra Inc., founded in 2004, has etched a significant footprint by concentrating on an often-underexplored niche: therapies for neurovascular and peripheral vascular diseases. The company began its journey focusing primarily on devices to treat conditions like strokes, introducing its first product, the Penumbra System, swiftly after its inception. By innovating in thrombectomy techniques, Penumbra has provided interventionalists with the tools to effectively remove clots in the brain and restore blood flow, a crucial factor in minimizing stroke damage. The firm's pioneering spirit and commitment to addressing the unmet needs in the medical field have propelled its growth, driven by an unyielding focus on enhancing clinical outcomes for patients facing critical vascular conditions. Penumbra's success hinges not just on innovative product development but also on a comprehensive business model that centers around high-impact therapeutic solutions. It generates revenue through the sale of these specialized medical devices, primarily to hospitals and healthcare facilities across the globe. By leveraging cutting-edge technology and collaboration with healthcare professionals, Penumbra continually broadens its product portfolio, including devices for peripheral vascular interventions and embolization therapies. This focus on expanding clinical applications and adapting to emerging medical challenges ensures that Penumbra stays at the forefront of innovation, enabling it to capture a growing share of the global healthcare market. Through its focused approach, Penumbra not only makes strides in advancing medical treatments but also fortifies its position as a formidable player in the field of therapeutic medical devices.

PEN Intrinsic Value
114.85 USD
Overvaluation 59%
Intrinsic Value
Price
Back to Top